Omeros’ Narsoplimab Led to Recovery of COVID Patients

A monoclonal antibody developed by Washington-based Omeros helped in the recovery of six hospitalized COVID-19 patients given the treatment in a compassionate use program, the company said.

The patients all had acute respiratory distress disorder and were on ventilators. All six patients recovered and no adverse effects were reported.

The company is currently seeking approval for the antibody, narsoplimab, as a treatment for a vascular disorder linked to transplants.